Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Cyclacel Pharmicals第一季度每股收益美元（2.27美元）超過預期（4.74美元），銷售額爲29.00萬美元
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(4.74) by 52.11 percent. This is a 67.8 percent increase over losses of $(7.05) per share from the same period last year. The company reported $29.00 thousand in sales this quarter.
Cyclacel Pharmicals（納斯達克股票代碼：CYCC）公佈的季度虧損爲每股2.27美元，比分析師普遍預期的4.74美元（4.74美元）高出52.11％。這比去年同期每股虧損7.05美元（7.05）增長了67.8％。該公司報告本季度銷售額爲29,000美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。